IRIS
LAVATELLI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.648
AS - Asia 2.657
EU - Europa 2.033
SA - Sud America 317
AF - Africa 148
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.811
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.566
CN - Cina 1.145
SG - Singapore 654
IE - Irlanda 550
HK - Hong Kong 287
RU - Federazione Russa 261
DE - Germania 240
FI - Finlandia 239
VN - Vietnam 234
BR - Brasile 231
IT - Italia 190
FR - Francia 124
UA - Ucraina 118
ZA - Sudafrica 105
GB - Regno Unito 97
IN - India 86
CA - Canada 44
SE - Svezia 42
JP - Giappone 40
BD - Bangladesh 33
TR - Turchia 33
AR - Argentina 29
ES - Italia 29
IQ - Iraq 26
PL - Polonia 26
MX - Messico 25
NL - Olanda 20
PK - Pakistan 18
MA - Marocco 17
VE - Venezuela 16
AT - Austria 13
BE - Belgio 13
LT - Lituania 13
ID - Indonesia 12
CO - Colombia 11
SA - Arabia Saudita 11
EC - Ecuador 10
AE - Emirati Arabi Uniti 8
IL - Israele 8
CZ - Repubblica Ceca 7
CL - Cile 6
KR - Corea 6
UY - Uruguay 6
AL - Albania 5
AU - Australia 5
AZ - Azerbaigian 5
EG - Egitto 5
ET - Etiopia 5
GR - Grecia 5
HU - Ungheria 5
MY - Malesia 5
PE - Perù 5
PT - Portogallo 5
UZ - Uzbekistan 5
IR - Iran 4
JM - Giamaica 4
JO - Giordania 4
PH - Filippine 4
SK - Slovacchia (Repubblica Slovacca) 4
TH - Thailandia 4
BO - Bolivia 3
CH - Svizzera 3
DZ - Algeria 3
EE - Estonia 3
LB - Libano 3
LK - Sri Lanka 3
LV - Lettonia 3
RS - Serbia 3
TN - Tunisia 3
BG - Bulgaria 2
BH - Bahrain 2
DK - Danimarca 2
EU - Europa 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
KG - Kirghizistan 2
MD - Moldavia 2
MN - Mongolia 2
NG - Nigeria 2
NP - Nepal 2
RO - Romania 2
VG - Isole Vergini Britanniche 2
AM - Armenia 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GH - Ghana 1
HN - Honduras 1
IS - Islanda 1
KE - Kenya 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
ME - Montenegro 1
MK - Macedonia 1
ML - Mali 1
MU - Mauritius 1
Totale 8.800
Salva come PNG Salva come JPEG
Città #
Dublin 550
Chandler 439
San Jose 413
Singapore 362
Ashburn 352
Dallas 310
Hong Kong 282
Beijing 274
Jacksonville 186
Nanjing 179
Boardman 167
Helsinki 122
Los Angeles 92
Johannesburg 89
Lauterbourg 84
Nanchang 84
Ho Chi Minh City 80
Princeton 80
Lawrence 77
Wilmington 72
Medford 71
New York 68
Hanoi 62
Munich 62
Shenyang 56
Hebei 55
Moscow 45
Council Bluffs 44
Jiaxing 44
Changsha 42
Buffalo 40
Shanghai 40
Ann Arbor 38
Hangzhou 38
Pavia 36
Santa Clara 35
Tokyo 34
Tianjin 33
Redondo Beach 31
São Paulo 30
Milan 27
Orem 27
Turku 23
Frankfurt am Main 20
Montreal 20
Norwalk 20
Warsaw 20
Piscataway 18
Woodbridge 18
Ankara 17
Chennai 16
London 15
Poplar 15
The Dalles 15
Boston 14
Chicago 14
Denver 14
Rio de Janeiro 14
San Francisco 14
Brussels 13
Atlanta 12
Avellino 12
Amsterdam 11
Brooklyn 11
Charlotte 11
Da Nang 11
Fairfield 11
Manchester 11
Seattle 11
Stockholm 11
Falkenstein 10
Haiphong 10
Mexico City 9
Washington 9
Catania 8
Chandigarh 8
Phoenix 8
Toronto 8
Baghdad 7
Caracas 7
Dhaka 7
Houston 7
Rome 7
Verona 7
Belo Horizonte 6
Biên Hòa 6
Campina Grande 6
Cape Town 6
Curitiba 6
Hải Dương 6
Jinan 6
Lahore 6
Ningbo 6
Nuremberg 6
Pune 6
Redwood City 6
Vienna 6
Addis Ababa 5
Bologna 5
Guangzhou 5
Totale 5.869
Salva come PNG Salva come JPEG
Nome #
Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. 210
A novel method for proteomic analysis of immunoglobulin light chains and attribution to a germline gene-based family 162
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 152
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 136
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 133
AMICA: an electronic patient record specifically designed for an amyloidosis network 133
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 132
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 131
Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality 129
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. 127
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 126
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 124
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 122
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 121
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 121
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 119
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 119
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 116
A practical approach to the diagnosis of systemic amyloidoses 116
Biochemical markers in early diagnosis and management of systemic amyloidoses 114
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 113
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 112
Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms 112
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 110
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 110
Prognostication of survival and progression to dialysis in AA amyloidosis 109
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 108
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 108
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 108
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 108
A workflow management system for the biological samples exchange within the amyloidosis network 107
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 107
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 107
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 106
AMICA: an electronic patient record specifically designed for an amyloidosis network. 106
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 106
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 103
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 102
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 102
IceTrack: a biobank information management system maximizing flexibility and usability 102
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 101
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 101
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 101
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 100
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 98
Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis 96
A workflow management system for the biological samples exchange within the amyloidosis network 95
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 95
Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains 94
Changes in tissue proteome associated with ATTR amyloidosis: Insights into pathogenesis 93
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 92
A case of monoclonal gammopathy of renal significance 92
Regulated expression of amyloidogenic immunoglobulin light chains in mice 91
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 90
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. 88
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient 88
Human wild-type and D76N β2-microglobulin variants are significant proteotoxic and metabolic stressors for transgenic C. elegans 83
Degradation versus fibrillogenesis, two alternative pathways modulated by seeds and glycosaminoglycans 83
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 83
A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils 82
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 81
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). 81
Age-related amyloidosis outside the brain: A state-of-the-art review 81
Dissecting the molecular features of systemic light chain (Al) amyloidosis: Contributions from proteomics 81
AA-amyloidosis in cats (Felis catus) housed in shelters 80
Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations 80
Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity 80
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 79
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 78
Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits 76
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis 75
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 75
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis 75
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 74
Renal alterations in cats (Felis catus) housed in shelters and affected by systemic AA-amyloidosis: Clinicopathological data, histopathology, and ultrastructural features 73
Truncation of the constant domain drives amyloid formation by immunoglobulin light chains 72
Clinical proteomics for diagnosis and typing of systemic amyloidoses 72
The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis 69
Clinical amyloid typing by proteomics: Performance evaluation and data sharing between two centres 68
Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. 64
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 62
Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations 59
The workings of the amyloid diseases. 59
Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration 58
Systemic amyloidoses and proteomics: The state of the art 57
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 54
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres 54
Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing 52
Proteomics in protein misfolding diseases. 50
A practical approach to the diagnosis of systemic amyloidoses 46
How do we improve treatments for patients with amyloidosis using proteomics? 46
Proteomics Fundamentally Advance the Diagnosis and Management of Amyloidosis 45
Perspectives in developments of mass spectrometry for improving diagnosis and monitoring of multiple myeloma and other plasma cell disorders 45
null 35
The Protein Network in Subcutaneous Fat Biopsies from Patients with AL Amyloidosis: More Than Diagnosis? 31
null 28
Renal amyloid‐A amyloidosis in cats: Characterization of proteinuria and biomarker discovery, and associations with kidney histology 23
Role of extracellular space and matrix remodeling in cardiac amyloidosis 10
null 6
Totale 8.969
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.820
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.820
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/2022308 2 5 2 4 6 2 6 39 20 3 38 181
2022/20231.410 181 116 18 82 120 121 10 59 623 8 32 40
2023/2024585 69 112 33 26 47 123 20 42 9 25 42 37
2024/20251.461 45 107 54 39 32 94 66 65 384 56 199 320
2025/20263.766 279 246 383 444 518 174 657 186 374 262 101 142
Totale 8.969